miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA
- 138 Downloads
Aberrant expression of miRNAs is crucial in several tissues tumorigenesis including thyroid. Recent studies demonstrated that miR-650 plays different role depending on the cancer type. Herein, we investigated the role of miR-650 in thyroid carcinoma.
The expression of miR-650 was analyzed in human thyroid tissues by q-RT-PCR. Anaplastic (8505C, CAL62, SW1736) and papillary (TPC-1) thyroid cancer cell lines were used to dissect the role of miR-650 on malignant hallmarks of transformation. Label-free proteomic analysis was exploited to unravel the targets of miR-650, while luciferase reporter assay and functional experiments were performed to confirm a selected target. Spearman’s rank correlation test was used to assess the association between miR-650 and its target in human thyroid cancer tissues.
miR-650 is over-expressed in anaplastic (ATC) thyroid carcinoma where it enhances cell migration and invasion. Proteomic label-free and bioinformatics analysis revealed that the serine-threonine protein phosphatase 2 catalytic subunit alpha (PPP2CA) is a target of miR-650; these finding were confirmed by luciferase assay. Restoration of PPP2CA mRNA, deprived of its 3′UTR, is able to revert the malignant phenotype induced by miR-650 in HEK-293 cells. Importantly, PPP2CA is down-regulated in ATC tissues and is inversely correlated with miR-650.
miR-650 displayed oncogenic activity in ATC cells through targeting PPP2CA phosphatase. These results suggest that miR-650/PPP2CA axis could be modulated to interfere with motile ability of thyroid carcinoma cells.
KeywordsmiR-650 PPP2CA Thyroid cancer Motility
We thank Gennaro Di Maro for its contribution in q-RT-PCR studies.
This study was funded by grants: “Bando di Ateneo per il sostegno alla partecipazione ai bandi di ricerca individuale (quota A per l’anno 2016 e 2017) e ricerca competitiva (quota C per l’anno 2016)” (code DSMB187) from University of Naples “Parthenope” to GS and SO, by 5 × 1000 IRCCS SDN (2013) and by Legge 5/2002 (Annualità 2007) Regione Campania.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.J. Kim, F. Yao, Z. Xiao, Y. Sun, L. Ma, MicroRNAs and metastasis: small RNAs play big roles. Cancer Metas. Rev. (2017). https://doi.org/10.1007/s10555-017-9712-y
- 3.G.S. Markopoulos, E. Roupakia, M. Tokamani, E. Chavdoula, M. Hatziapostolou, C. Polytarchou, K.B. Marcu, A.G. Papavassiliou, R. Sandaltzopoulos, E. Kolettas, A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol 40(4), 303–339 (2017). https://doi.org/10.1007/s13402-017-0341-9 CrossRefGoogle Scholar
- 7.J.Y. Huang, S.Y. Cui, Y.T. Chen, H.Z. Song, G.C. Huang, B. Feng, M. Sun, W. De, R. Wang, L.B. Chen, MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE 8(8), e72615 (2013). https://doi.org/10.1371/journal.pone.0072615 CrossRefGoogle Scholar
- 8.M. Lango-Chavarria, G.K. Chimal-Ramirez, M.E. Ruiz-Tachiquin, N.A. Espinoza-Sanchez, M.C. Suarez-Arriaga, E.M. Fuentes-Panana, A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients. Int. J. Oncol. 50(2), 432–440 (2017). https://doi.org/10.3892/ijo.2017.3842 CrossRefGoogle Scholar
- 11.M. Mraz, D. Dolezalova, K. Plevova, K. Stano Kozubik, V. Mayerova, K. Cerna, K. Musilova, B. Tichy, S. Pavlova, M. Borsky, J. Verner, M. Doubek, Y. Brychtova, M. Trbusek, A. Hampl, J. Mayer, S. Pospisilova, MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood 119(9), 2110–2113 (2012). https://doi.org/10.1182/blood-2011-11-394874 CrossRefGoogle Scholar
- 13.E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazzi, S. Sellari-Franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti, R. Elisei, Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nature reviews. Endocrinology. (2017). https://doi.org/10.1038/nrendo.2017.76
- 16.M. Saiselet, J.M. Pita, A. Augenlicht, G. Dom, M. Tarabichi, D. Fimereli, J.E. Dumont, V. Detours, C. Maenhaut, miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers. Oncotarget 7(32), 52475–52492 (2016). https://doi.org/10.18632/oncotarget.9655 CrossRefGoogle Scholar
- 19.E. Nigro, E. Imperlini, O. Scudiero, M.L. Monaco, R. Polito, G. Mazzarella, S. Orru, A. Bianco, A. Daniele, Differentially expressed and activated proteins associated with non small cell lung cancer tissues. Respir. Res. 16, 74 (2015). https://doi.org/10.1186/s12931-015-0234-2 CrossRefGoogle Scholar
- 21.S. Spaziani, E. Imperlini, A. Mancini, M. Caterino, P. Buono, S. Orru, Insulin-like growth factor 1 receptor signaling induced by supraphysiological doses of IGF-1 in human peripheral blood lymphocytes. Proteomics. 14(13-14), 1623–1629 (2014). https://doi.org/10.1002/pmic.201300318 CrossRefGoogle Scholar
- 22.M. Caterino, A. Pastore, M.G. Strozziero, G. Di Giovamberardino, E. Imperlini, E. Scolamiero, L. Ingenito, S. Boenzi, F. Ceravolo, D. Martinelli, C. Dionisi-Vici, M. Ruoppolo, The proteome of cblC defect: in vivo elucidation of altered cellular pathways in humans. J. Inherit. Metab. Dis. 38(5), 969–979 (2015). https://doi.org/10.1007/s10545-014-9806-4 CrossRefGoogle Scholar
- 23.E. Minna, P. Romeo, M. Dugo, L. De Cecco, K. Todoerti, S. Pilotti, F. Perrone, E. Seregni, L. Agnelli, A. Neri, A. Greco, M.G. Borrello, miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. Oncotarget 7(11), 12731–12747 (2016). https://doi.org/10.18632/oncotarget.7262 CrossRefGoogle Scholar
- 27.W.W. Chien, C. Domenech, R. Catallo, T. Kaddar, J.P. Magaud, G. Salles, M. Ffrench, Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. Oncogene 30(16), 1880–1891 (2011). https://doi.org/10.1038/onc.2010.570 CrossRefGoogle Scholar
- 28.M.L. Slattery, L.E. Mullany, L. Sakoda, W.S. Samowitz, R.K. Wolff, J.R. Stevens, J.S. Herrick, The NF-kappaB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression. J. Cancer Res. Clin. Oncol. (2017). https://doi.org/10.1007/s00432-017-2548-6
- 39.A.P. Singh, S. Bafna, K. Chaudhary, G. Venkatraman, L. Smith, J.D. Eudy, S.L. Johansson, M.F. Lin, S.K. Batra, Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett. 259(1), 28–38 (2008). https://doi.org/10.1016/j.canlet.2007.09.018 CrossRefGoogle Scholar
- 41.J. Li, C. Sheng, W. Li, J.H. Zheng, Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma. Int. J. Clin. Exp. Pathol. 7(3), 1147–1153 (2014)Google Scholar
- 44.A. Bhardwaj, S. Singh, S.K. Srivastava, S. Arora, S.J. Hyde, J. Andrews, W.E. Grizzle, A.P. Singh, Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model. Br. J. Cancer 110(8), 2000–2010 (2014). https://doi.org/10.1038/bjc.2014.141 CrossRefGoogle Scholar
- 46.C.M. O’Connor, A. Perl, D. Leonard, J. Sangodkar, G. Narla, Therapeutic Targeting of PP2A. Int. J. Biochem. Cell Biol. (2017). https://doi.org/10.1016/j.biocel.2017.10.008
- 48.I. Cristobal, L. Garcia-Orti, C. Cirauqui, X. Cortes-Lavaud, M.A. Garcia-Sanchez, M.J. Calasanz, M.D. Odero, Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97(4), 543–550 (2012). https://doi.org/10.3324/haematol.2011.050542 CrossRefGoogle Scholar
- 49.I. Cristobal, L. Garcia-Orti, C. Cirauqui, M.M. Alonso, M.J. Calasanz, M.D. Odero, PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25(4), 606–614 (2011). https://doi.org/10.1038/leu.2010.294 CrossRefGoogle Scholar